Literature DB >> 32454975

Predictors for upstaging of ductal carcinoma in situ (DCIS) to invasive carcinoma in non-mass-type DCIS.

Goshi Oda1, Tsuyoshi Nakagawa1, Ayumi Ogawa1, Yuichi Kumaki1, Tokuko Hosoya1, Hitoshi Sugimoto1, Toshiyuki Ishiba1, Mori Mio2, Tomoyuki Fujioka2, Kazunori Kubota2, Iichiroh Onishi3, Hiroyuki Uetake1.   

Abstract

Preoperatively diagnosed ductal carcinoma in situ (DCIS) is sometimes upstaged to invasive cancer by postoperative pathological examination. Various preoperative factors associated with upstaging to invasive cancer have been reported; however, this subject remains to be clarified. DCIS takes various forms on imaging, but many cases show non-mass-type lesions. In non-mass-type DCIS, recognizing the presence of invasion is difficult. To investigate predictors associated with upstaging to invasive cancer more precisely, we examined only non-mass-type DCIS. The present study retrospectively analyzed 101 patients diagnosed with non-mass-type DCIS preoperatively on breast biopsy at our institution between 2007 and 2017. Data were analyzed using Fisher's exact probability test and two-sample t-tests. Multivariate analysis was performed using logistic regression. The results showed that 27 patients (27%) were finally diagnosed with invasive cancer. Univariate analysis revealed abnormal result of palpation on breast examination (P=0.05), comedo necrosis (P=0.05), and HER2 status (P=0.02) as significant predictors. Multivariate analysis revealed an abnormal result of palpation as an independent predictor of invasive cancer underestimation (odds ratio 4.76; confidence interval 1.44-15.7; P=0.01). In conclusion, preoperatively diagnosed non-mass-type DCIS represented an underestimation in approximately 27% of cases. In particular, the presence of a clinically abnormal palpation increases the chance of upstaging to invasive cancer.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  DCIS; breast cancer; non-mass-type DCIS

Year:  2020        PMID: 32454975      PMCID: PMC7243301          DOI: 10.3892/mco.2020.2036

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  18 in total

1.  The significance of mammotome core biopsy specimens without radiographically identifiable microcalcification and their influence on surgical management--a retrospective review with histological correlation.

Authors:  D Cox; S Bradley; D England
Journal:  Breast       Date:  2005-08-02       Impact factor: 4.380

2.  Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.

Authors:  Meagan E Brennan; Robin M Turner; Stefano Ciatto; M Luke Marinovich; James R French; Petra Macaskill; Nehmat Houssami
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

3.  Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus.

Authors:  Jong Won Lee; Wonshik Han; Eunyoung Ko; Jihyoung Cho; Eun-Kyu Kim; So-Youn Jung; Nariya Cho; Woo Kyung Moon; In-Ae Park; Dong-Young Noh
Journal:  J Surg Oncol       Date:  2008-07-01       Impact factor: 3.454

4.  Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.

Authors:  Tina W F Yen; Kelly K Hunt; Merrick I Ross; Nadeem Q Mirza; Gildy V Babiera; Funda Meric-Bernstam; S Eva Singletary; W Fraser Symmans; Sharon H Giordano; Barry W Feig; Frederick C Ames; Henry M Kuerer
Journal:  J Am Coll Surg       Date:  2005-04       Impact factor: 6.113

5.  A mass on breast imaging predicts coexisting invasive carcinoma in patients with a core biopsy diagnosis of ductal carcinoma in situ.

Authors:  T A King; G H Farr; G J Cederbom; D H Smetherman; J S Bolton; A J Stolier; G M Fuhrman
Journal:  Am Surg       Date:  2001-09       Impact factor: 0.688

6.  Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision.

Authors:  M L Darling; D N Smith; S C Lester; C Kaelin; D L Selland; C M Denison; P J DiPiro; D I Rose; E Rhei; J E Meyer
Journal:  AJR Am J Roentgenol       Date:  2000-11       Impact factor: 3.959

7.  Large palpable ductal carcinoma in situ is Her-2 positive with high nuclear grade.

Authors:  Ahmad Monabati; Ali-Reza Sokouti; Sadat Noori Noori; Akbar Safaei; Abd-Rasul Talei; Shapoor Omidvari; Negar Azarpira
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

8.  The Relationships between HER2 Overexpression and DCIS Characteristics.

Authors:  Pamela Di Cesare; Lorenzo Pavesi; Laura Villani; Andrea Battaglia; Gian Antonio Da Prada; Alberto Riccardi; Mara Frascaroli
Journal:  Breast J       Date:  2016-12-10       Impact factor: 2.431

9.  Preoperatively diagnosed ductal carcinoma in situ: risk prediction of invasion and effects on axillary management.

Authors:  Yuya Sato; Takayuki Kinoshita; Junko Suzuki; Kenjiro Jimbo; Sota Asaga; Takashi Hojo; Masayuki Yoshida; Hitoshi Tsuda
Journal:  Breast Cancer       Date:  2015-09-01       Impact factor: 4.239

10.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

View more
  2 in total

Review 1.  Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2.

Authors:  Julia Solek; Jedrzej Chrzanowski; Adrianna Cieslak; Aleksandra Zielinska; Dominika Piasecka; Marcin Braun; Rafal Sadej; Hanna M Romanska
Journal:  Biomedicines       Date:  2022-05-03

2.  Breast cancer in Trinidad and Tobago: Etiopathogenesis, histopathology and receptor study.

Authors:  Srikanth Umakanthan; Maryann Bukelo; Vijay Kumar Chattu; Ravi Maharaj; Nicole N Khan; Katherine Keane; Nick Khadoo; Aliyyah Khan; Amaara Khan; Ronny Kong; Selina Korkmaz; Anvesh Kovoor
Journal:  J Family Med Prim Care       Date:  2021-12-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.